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Abstract
Background: The burden of disease due to S. pneumoniae (pneumococcus), particularly pneumonia, remains high
despite the widespread use of vaccines. Drug resistant strains complicate clinical treatment and may increase costs.
We estimated the annual burden and incremental costs attributable to antibiotic resistance in pneumococcal
pneumonia.
Methods: We derived estimates of healthcare utilization and cost (in 2012 dollars) attributable to penicillin,
erythromycin and fluoroquinolone resistance by taking the estimate of disease burden from a previously described
decision tree model of pneumococcal pneumonia in the U.S. We analyzed model outputs assuming only the
existence of susceptible strains and calculating the resulting differences in cost and utilization. We modeled the
cost of resistance from delayed resolution of illness and the resulting additional health services.
Results: Our model estimated that non-susceptibility to penicillin, erythromycin and fluoroquinolones directly
caused 32,398 additional outpatient visits and 19,336 hospitalizations for pneumococcal pneumonia. The incremental
cost of antibiotic resistance was estimated to account for 4% ($91 million) of direct medical costs and 5% ($233 million)
of total costs including work and productivity loss. Most of the incremental medical cost ($82 million) was related to
hospitalizations resulting from erythromycin non-susceptibility. Among patients under age 18 years, erythromycin
non-susceptibility was estimated to cause 17% of hospitalizations for pneumonia and $38 million in costs, or 39% of
pneumococcal pneumonia costs attributable to resistance.
Conclusions: We estimate that antibiotic resistance in pneumococcal pneumonia leads to substantial healthcare
utilization and cost, with more than one-third driven by macrolide resistance in children. With 5% of total
pneumococcal costs directly attributable to resistance, strategies to reduce antibiotic resistance or improve antibiotic
selection could lead to substantial savings.
Keywords: Streptococcus pneumoniae, Antibiotic resistance, Healthcare utilization, DRSP
Background
Streptococcus pneumoniae (pneumococcus) causes a var-
iety of clinical syndromes, including acute otitis media,
pneumonia, and meningitis. Although several pneumo-
coccal vaccines have been developed (including pneu-
mococcal polysaccharide vaccine 23 (PPSV23) in 1983,
pneumococcal conjugate vaccine 7 (PCV7) in 2000, and
pneumococcal conjugate vaccine 13 (PCV13) in 2010),
the burden of pneumococcal disease remains high across
age groups, in the United States and abroad [1-10]. Our
previously published model of pneumococcal burden in
the United States estimated that pneumococcus was re-
sponsible for 4 million disease episodes in 2004, with
acute otitis media in children accounting for the majo-
rity of cases [11]. Vaccination has led to large reductions
for invasive pneumococcal diseases, yet Active Bacterial
Core surveillance (ABCs) identified approximately 36,850
cases of invasive pneumococcal disease in the US in
2011 [12]. This continued high incidence of invasive
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by non-vaccine serotypes [13,14].
A major concern for treatment of pneumococcal dis-
ease is the increasing frequency of antibiotic resistance
[15]. These strains are primarily resistant to penicillin,
macrolides and, to a lesser extent, fluoroquinolones [16].
Among the 36,850 invasive pneumococcal disease cases
identified by ABCs in 2011, 9% were caused by penicillin
non-susceptible strains and 26% were caused by erythro-
mycin non-susceptible strains [12]. In addition, despite
overall reductions in the incidence of resistant IPD, the
prevalence of some multi-drug resistant strains, such as
serotype 19A in the United States, increased due to se-
rotype replacement and capsular switching following the
introduction of PCV7 in 2000 [15,17,18]. The financial
impact of antibiotic-resistant pneumococcus has not been
evaluated and is likely to depend upon many factors in-
cluding whether antibiotic treatment is concordant or dis-
cordant with the susceptibility profile of the infecting
strain. Discordant treatment may result in delayed cure,
multiple outpatient visits or hospitalization, and increases
in morbidity, mortality and cost.
We used a previously developed decision tree-based
model of U.S. pneumococcal disease burden to estimate
the impact of antibiotic resistance upon healthcare uti-
lization and cost [11]. We focused our analysis on pneu-
monia, as our prior study found that pneumococcal
pneumonia accounted for 866,000 annual cases (22%
of pneumococcal disease burden) and $4.9 billion dollars,
or 72%, of total healthcare and time-related costs attribu-
table to pneumococcal disease.
Methods
We assessed the attributable burden of resistance using
a previously published decision-tree model of pneumo-
coccal disease burden in the United States in 2004 [11].
Model inputs and assumptions for an example pediatric
(0- <5 yrs) and adult (50- <65 yrs) age group are pro-
vided in Table 1. All uses of the term “resistance” denote
the combination of intermediate or high level resistance.
Since minimum inhibitory concentration (MIC) break-
points for penicillin were changed in 2008, we performed
most analyses using both old and new sets of breakpoints.
We assumed that the effects of antibiotic resistance oc-
curred only in the presence of discordance between the
antibiotic chosen for treatment and the susceptibility
of the infecting organism. From expert opinion, we esti-
mated what fraction of patients with discordant therapy
would have delayed cure, resulting in additional out-
patient visits, courses of antibiotics, or hospitalization.
We further assumed that inpatient antibiotic coverage
was sufficiently broad that treatment failure resulting
from discordant therapy only occurred in the outpatient
setting. This study was exempted from human research
oversight by the Harvard Pilgrim Health Care Institutional
Review Board.
Table 1 Inputs and assumptions for outpatient pneumococcal pneumonia for sample pediatric and adult age groups:
0- <5 and 50-< 65 years*
Outcomes (% Cases)
Concordant treatment Discordant treatment
Sample
age groups
Antibiotic % cases
receiving
antibiotic
% cases
treated
discordantly
% simple
cure
% delayed
cure
% delayed
cure and
hospitalized
% simple
cure
% delayed
cure
% delayed
cure and
hospitalized
Pediatric
(0-< 5 yrs)
Amoxicillin (High dose) 9% 37% 71% 24% 5% 69% 23% 8%
Amoxicillin (Low dose) 7% 37% 71% 24% 5% 68% 23% 9%
Augmentin 11% 37% 71% 24% 5% 69% 23% 8%
Azithromycin 28% 32% 71% 24% 5% 45% 15% 40%
Oral Cephalosporin
(2
nd generation)
7% 8% 71% 24% 5% 68% 22% 10%
Oral Cephalosporin
(3
rd generation)
24% 8% 71% 24% 5% 68% 22% 10%
IM Ceftriaxone 14% 8% 71% 24% 5% 68% 23% 10%
Adult
(50-< 65 yrs)
Amoxicillin 2% 37% 81% 14% 5% 77% 14% 9%
Augmentin 19% 37% 81% 14% 5% 77% 14% 9%
Azithromycin 15% 29% 81% 14% 5% 51% 9% 40%
Oral Cephalosporin
(3rd generation)
9% 6% 81% 14% 5% 77% 14% 10%
IM Ceftriaxone 5% 6% 81% 14% 5% 77% 14% 10%
Fluoroquinolones 56% 1% 81% 14% 5% 51% 9% 40%
*Derived from reference 11. Two age groups are shown as examples of model assumptions and inputs.
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tained from the 2004–2005 National Ambulatory Med-
ical Care Survey and 2004–2005 National Hospital
Ambulatory Medical Care Survey using ICD-9 codes (all
primary and secondary diagnoses) by age. We restric-
ted outpatient cases to those visits during which an an-
tibiotic was prescribed. Using expert panel consensus
described elsewhere, we corrected for age-specific over-
diagnosis among outpatient cases (16% for pneumonia)
[11]. Also using expert opinion, we estimated the frequen-
cy of relevant treatment outcomes, based upon antibiotic
susceptibility profiles. The distribution of agents pres-
cribed was obtained from the National Ambulatory Me-
dical Care Survey. The incidence of inpatient pneumonia
cases was obtained from the 2004 National Hospital Dis-
charge Survey and the 2004 National Inpatient Sample
using ICD-9 codes (primary diagnosis only) by age. For
cases requiring hospital admission, we estimated the likeli-
hood of follow-up outpatient visits, nursing home stays
and death from expert opinion and literature review. We
used estimates of the number of inpatient and outpatient
pneumonia cases in 2004 involving pneumococcal isolates
resistant to penicillin, erythromycin and fluoroquinolones
by age group from Active Bacterial Core Surveillance data
(inpatient) and primary literature (outpatient). In our pre-
vious analyses using this model we assumed current
prevalence of antibiotic resistance [11].
Cost associated with total pneumococcal disease bur-
den (both sensitive and resistant strains) was estimated
in our previously published paper using a combination
of sources including the Federal Register, and public and
private payor rates. We examined four categories of cost:
1) direct costs (including medical care), 2) costs from
adverse outcomes, 3) work-loss costs, and 4) cost from
lost wages. We conducted several sensitivity analyses re-
lated to cost in this manuscript, including an analysis for
cost per hospital day. Further details on estimations of
cost are provided in Appendices C-E of that manuscript
[11]. To derive an estimate of healthcare utilization and
costs due to medical visits and work loss (in 2012 dollars)
attributable solely to resistance to penicillin, erythromycin
and fluoroquinolones, we analyzed model outputs assu-
ming only the existence of susceptible strains and calcu-
lating the resulting differences in cost and utilization.
Resistant disease was assumed to be more likely to re-
sult in delayed cure, and, if not treated with concordant
Table 2 Estimated pneumonia burden due to antibiotic-resistant Streptococcus pneumoniae isolates
Age (years)
0- < 5 5- < 18 18- < 50 50- < 65 65+ Total
Inpatient cases
N (% of total) 40,386 (10%) 16,772 (4%) 42,789 (11%) 59,508 (15%) 241,827 (60%) 401,282
Susceptible isolates (pre-2008 MIC) 32,963 (82%) 14,284 (85%) 38,329 (90%) 52,804 (89%) 215,160 (89%) 353,543
Susceptible isolates (post-2008 MIC) 36,799 (91%) 15,251 (91%) 40,877 (96%) 56,559 (95%) 231,704 (96%) 381,190
PCN resistant isolates (pre-2008 MIC)* 14,375 (36%) 3,522 (21%) 8,130 (19%) 12,497 (21%) 58,038 (24%) 96,562
PCN resistant isolates (post-2008 MIC) 4,846 (12%) 1,174 (7%) 1,711 (4%) 2,975 (5%) 12,901 (5%) 23,607
ERY resistant isolates 10,821 (26%) 3,250 (19%) 7,296 (17%) 10,811 (18%) 48,754 (20%) 80,932
FQ resistant isolates 404 (1%) 168 (1%) 428 (1%) 595 (1%) 2,616 (1%) 4,211
Multiply resistant isolates (pre-2008 MIC) 8,562 (21%) 2,084 (12%) 4,927 (12%) 7,603 (13%) 36,375 (15%) 59,551
Multiply resistant isolates (post-2008 MIC) 2,926 (7%) 716 (4%) 1,095 (3%) 1,893 (3%) 8,115 (3%) 14,745
Outpatient cases
N (% of total) 119,613(26%) 88,810 (19%) 116,427 (25%) 78,154 (17%) 61,519 (13%) 464,523
Susceptible isolates (pre-2008 MIC) 97,791 (82%) 72,608 (82%) 101,297 (87%) 67,216 (86%) 53,524 (87%) 392,436
Susceptible isolates (post-2008 MIC) 106,974 (89%) 79,427 (89%) 112,860 (97%) 74,729 (96%) 59,630 (97%) 433,620
PCN resistant isolates (pre-2008 MIC) 44,257 (37%) 32,860 (37%) 43,078 (37%) 28,917 (37%) 22,762 (37%) 171,873
PCN resistant isolates (post-2008 MIC) 14,354 (12%) 10,657 (12%) 9,314 (8%) 7,034 (9%) 4,922 (8%) 46,281
ERY resistant isolates 37,728 (32%) 28,012 (32%) 33,532 (29%) 22,509 (29%) 17,718 (29%) 139,499
FQ resistant isolates 1,196 (1%) 888 (1%) 1,164 (1%) 782 (1%) 681 (1%) 4,711
Multiply resistant isolates (pre-2008 MIC) 31,147 (26%) 23,126 (26%) 28,595 (25%) 19,195 (25%) 15,141 (25%) 117,204
Multiply resistant isolates (post-2008 MIC) 10,634 (9%) 7,895 (9%) 6,615 (6%) 4,968 (6%) 3,550 (6%) 33,662
*In January 2008, the Clinical and Laboratory Standards Institute revised the minimum inhibitory concentration (MIC) for non-susceptibility to penicillin.
Notes: PCN = penicillin, ERY = erythromycin, FQ = fluoroquinolone. “Resistant” includes intermediate and non-susceptible isolates. Data sources: Active Bacterial
Core Surveillance data (inpatient) and primary literature (outpatient). Resistance categories are not mutually exclusive, as some strains exhibited resistance to
multiple antibiotics.
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costs. For outpatient cases with delayed cure, cost attribu-
table to resistance reflected additional outpatient visits,
courses of antibiotics, or hospitalization. No changes in
initial antibiotic therapy were assumed.
Finally, we performed sensitivity analyses to model the
projected attributable costs resulting from increases, from
present levels, in resistance to penicillin, erythromycin
and fluoroquinolones. We assumed antibiotic resistant
strains would replace sensitive strains, resulting in stable
overall prevalence of pneumococcal disease; this assump-
tion is partly supported by several studies in children fin-
ding that overall carriage rates of pneumococcus in the
nasopharynx remained stable despite serotype replace-
ment with resistant strains after conjugate vaccination
[19-21]. We further assumed that the amount of disease
and frequency of treatment failure due to resistant strains
would remain similar.
Results
Overall inpatient pneumococcal pneumonia burden was
estimated to be highest among those over age 65, while
outpatient visits for pneumonia were most common
among children less than 5 years old (Table 2). Using
current MIC breakpoints, 23% (93,853 of 401,282) of in-
patient cases and 34% (156,496 of 464,523) of outpatient
cases exhibited resistance to at least one antibiotic. Re-
sistance occurred most frequently to macrolides, with
20% of inpatient cases (80,932 of 401,282) and 30% of out-
patient cases (139,499 of 464,523) exhibiting resistance.
To provide perspective, we also calculated resistance
profiles using pre-2008 MIC breakpoints and estimated
Table 3 Estimated annual healthcare utilization attributable to antibiotic resistant strains of pneumococcus for
all ages*
Children (age <18) Adults (age ≥18) Total (all ages)
Attributable to PCN resistance
Hospitalizations** 867 471 1,338
Outpatient visits 1,478 780 2,258
Direct medical costs*** 3,023,332 2,864,498 5,887,829
Total costs 5,358,139 8,916,750 14,274,155
Attributable to ERY resistance
Hospitalizations 9,711 7,889 17,600
Outpatient visits 16,557 12,933 29,490
Direct medical costs 35,443,768 47,185,234 82,629,002
Total costs 68,096,627 143,766,210 211,862,838
Attributable to FQ resistance
Hospitalizations 0 399 399
Outpatient visits 0 650 650
Direct medical costs 0 2,425,796 2,425,796
Total costs 0 6,935,208 6,935,208
Attributable to PCN, ERY, or FQ resistance
Hospitalizations 10,578 8,758 19,336
Outpatient visits 18,035 14,363 32,398
Direct medical costs 38,467,099 52,475,527 90,942,627
Total costs 73,454,767 159,617,433 233,072,201
All cases (susceptible and resistant)
Hospitalizations 57,158 344,124 401,282
Outpatient visits 435,967 729,334 1,165,301
Direct medical costs 265,374,908 2,295,429,821 2,560,804,729
Total costs 555,738,333 4,407,889,411 4,963,627,745
Note: PCN = penicillin, ERY = erythromycin, FQ = fluoroquinolone. “Resistant” includes intermediate and non-susceptible isolates. Post-2008 MIC breakpoints were
used for penicillin resistance.
*All hospitalizations due to resistance were the result of failed therapy for patients treated initially in the outpatient setting.
**Hospitalizations include admissions from the emergency department.
***All costs are expressed in 2012 dollars. Direct medical costs exclude work and productivity loss.
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cases and 42% (197,680 of 464,523) of outpatient cases
of pneumococcal pneumonia involved resistance to one
or more of the three antibiotics studied. Using pre-2008
breakpoints, resistance would have occurred most fre-
quently to penicillin, with nearly 50% (59,551 of 121,503) of
resistant inpatient isolates and 60% (117,204 of 197,680) of
resistant outpatient isolates exhibiting resistance to multiple
antibiotics.
Our model estimated that resistance to penicillin, ery-
thromycin and fluoroquinolones directly caused 32,398
excess outpatient visits and 19,336 excess hospitaliza-
tions for pneumonia (Table 3). Overall, the incremental
cost of antibiotic resistance was estimated to account for
4% ($91 million) of annual pneumococcal pneumonia
direct medical costs and 5% ($233 million) of total costs
(including work and productivity loss). Most of the incre-
mental medical cost ($82 of $91 million) was estimated to
be due to hospitalizations resulting from erythromycin re-
sistance. Among the 139,499 cases of outpatient pneumo-
nia resistance to erythromycin, we estimated from expert
opinion that 50,285 of these cases (36%) were actually
treated with erythromycin. Among these 50,285 cases
given discordant treatment, 49% still resulted in simple
cure, 11% resulted in delayed outpatient resolution and
40% resulted in hospitalization due to failure to improve.
While pediatric patients contributed to fewer than
15% of inpatient pneumonia cases, they constituted 45%
of outpatient cases. Since costs attributable to antibiotic
resistance resulted from failure of outpatient cases only,
discordant treatment of pediatric cases contributed sig-
nificantly to overall healthcare utilization and costs re-
lated to resistance. In particular, erythromycin resistance
among patients under age 18 caused 17% of hospitaliza-
tions—that otherwise would not have occurred—and $38
million in costs.
The projected costs of future increases in resistance
(vs. baseline costs from 2004 estimates, expressed in
2012 dollars) to specific antibiotics are shown in Figure 1.
This figure assumes a linear relationship between the
number of resistant cases and the associated cost. In-
creased resistance to erythromycin was associated with
the greatest projected cost.
Discussion
We estimated that more than one-third of pneumococcal
pneumonia cases involved resistance to penicillin, eryth-
romycin or fluoroquinolones. While antibiotic-resistant
strains accounted for a substantial portion of inpatient
and outpatient pneumococcal pneumonia cases, resistance
itself was responsible for a far lower percentage of total
pneumococcal pneumonia medical costs (4%) and total
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discordant therapy and the resulting treatment failure
were assumed to only occur in the outpatient setting.
Because empiric therapy recommended by national guide-
lines address resistant infections, we assumed that in-
patient treatment would cover resistant organisms for
community-acquired pneumococcal pneumonia [22,23].
Nevertheless, costs attributable to resistance amount to
over $90 million in direct medical and $230 million in
total costs. Nearly all costs associated with antibiotic re-
sistance resulted from outpatient discordant therapy that
led to delays in cure, ultimately requiring additional cour-
ses of antibiotics, additional outpatient visits or hospitali-
zation for resolution.
While resistance to penicillin was the most common,
the majority of associated costs were due to erythro-
mycin resistance. In particular, macrolide resistant pneu-
monia in children comprised 39% of total associated costs
due to resistance, primarily resulting from hospitalization
of cases initially treated in the outpatient setting. From
expert opinion, we estimated that 32% of pediatric outpa-
tient pneumococcal pneumonia cases treated with eryth-
romycin were discordant, resulting in an additional 9700
hospitalizations annually due to delayed resolution. To ad-
dress the threat of macrolide failure, recent guidelines on
community-acquired pneumonia from the Pediatric Infec-
tious Disease Society recommend amoxicillin as first line
therapy, with macrolides recommended only if there is
suggestion of infection with atypical organisms [22].
Based upon our projections of increased costs due to
rising levels of antibiotic resistance, increases in erythro-
mycin resistance are most likely to result in significant
increases in cost. This is in agreement with our finding
that delayed cure after treatment with erythromycin,
predominantly in the pediatric population, is responsible
for the majority of costs currently associated with anti-
biotic resistant pneumococcal infections. Projected in-
creases in resistance are simply reasonable guesses based
on current levels of resistance; more dramatic increases
in resistance are certainly possible, and would be associ-
ated with greater increases in cost.
This study has several limitations. We estimated the
impact of antibiotic resistance using an existing decision
tree model of pneumococcal disease burden from 2004.
The burden of antibiotic resistant cases of pneumococcal
pneumonia may have changed substantially since then.
We also assumed that antibiotic resistance among non-
bacteremic cases was similar to bacteremic cases. In ad-
dition, the effects of the 2010 PCV13 introduction on
disease burden are not reflected in these estimates. For
example, emerging antibiotic resistance in replacement
non-vaccine serotypes are difficult to predict and are not
addressed in this pre-PCV13 model. Our model benefits
from incorporation of extensive data from administrative
data sources and an expert panel; however the results
are highly sensitive to assumptions about the frequency
of discordant therapy for which we did not directly collect
data. Our model also assumed that the costs of antibiotic
resistance were exclusively due to additional treatment
failure for cases initially treated in the outpatient setting;
this assumption does not account for the possibility of
additional delayed cure among inpatients. However, we
believe that the use of broad-spectrum antibiotics for in-
patient treatment renders delayed cure much less likely in
this setting. In our sensitivity analyses, we assumed that
rising resistance would have no effect on virulence; how-
ever it has been shown that serotypes differ in their ability
to cause disease and thus we likely under-estimated the
projected cost associated with increased levels of antibiotic
resistant strains [24]. Lastly, we assumed that further in-
creases in resistant strains would not result in changes in
empirical prescribing practices, although this is likely if
levels of resistance substantially rise.
Despite the introduction of pneumococcal vaccines,
the burden of pneumococcal pneumonia remains high.
While we estimated that antibiotic resistance was only as-
sociated with 4% of total pneumococcal healthcare costs,
the absolute cost attributed to antibiotic resistance and
treatment failure was considerable. Strategies to reduce
antibiotic resistance or improve antibiotic selection may
prevent a significant number of hospitalizations and out-
patient visits and lead to a substantial savings.
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